JP2022031762A5 - - Google Patents

Download PDF

Info

Publication number
JP2022031762A5
JP2022031762A5 JP2021189167A JP2021189167A JP2022031762A5 JP 2022031762 A5 JP2022031762 A5 JP 2022031762A5 JP 2021189167 A JP2021189167 A JP 2021189167A JP 2021189167 A JP2021189167 A JP 2021189167A JP 2022031762 A5 JP2022031762 A5 JP 2022031762A5
Authority
JP
Japan
Prior art keywords
composition according
cannabis
cannabidiol
hydrogen
cation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021189167A
Other languages
English (en)
Japanese (ja)
Other versions
JP7284241B2 (ja
JP2022031762A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/028953 external-priority patent/WO2017185038A1/en
Application filed filed Critical
Publication of JP2022031762A publication Critical patent/JP2022031762A/ja
Publication of JP2022031762A5 publication Critical patent/JP2022031762A5/ja
Priority to JP2023081364A priority Critical patent/JP7671079B2/ja
Application granted granted Critical
Publication of JP7284241B2 publication Critical patent/JP7284241B2/ja
Priority to JP2025065534A priority patent/JP2025108565A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021189167A 2016-04-22 2021-11-22 即効性の植物由来医薬化合物及び栄養補給剤 Active JP7284241B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023081364A JP7671079B2 (ja) 2016-04-22 2023-05-17 即効性の植物由来医薬化合物及び栄養補給剤
JP2025065534A JP2025108565A (ja) 2016-04-22 2025-04-11 即効性の植物由来医薬化合物及び栄養補給剤

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662326490P 2016-04-22 2016-04-22
US62/326,490 2016-04-22
US201662429544P 2016-12-02 2016-12-02
US62/429,544 2016-12-02
PCT/US2017/028953 WO2017185038A1 (en) 2016-04-22 2017-04-21 Fast-acting plant-based medicinal compounds and nutritional supplements
JP2019506612A JP6983868B2 (ja) 2016-04-22 2017-04-21 即効性の植物由来医薬化合物及び栄養補給剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019506612A Division JP6983868B2 (ja) 2016-04-22 2017-04-21 即効性の植物由来医薬化合物及び栄養補給剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023081364A Division JP7671079B2 (ja) 2016-04-22 2023-05-17 即効性の植物由来医薬化合物及び栄養補給剤

Publications (3)

Publication Number Publication Date
JP2022031762A JP2022031762A (ja) 2022-02-22
JP2022031762A5 true JP2022031762A5 (https=) 2022-06-09
JP7284241B2 JP7284241B2 (ja) 2023-05-30

Family

ID=60117058

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019506612A Active JP6983868B2 (ja) 2016-04-22 2017-04-21 即効性の植物由来医薬化合物及び栄養補給剤
JP2021189167A Active JP7284241B2 (ja) 2016-04-22 2021-11-22 即効性の植物由来医薬化合物及び栄養補給剤
JP2023081364A Active JP7671079B2 (ja) 2016-04-22 2023-05-17 即効性の植物由来医薬化合物及び栄養補給剤
JP2025065534A Pending JP2025108565A (ja) 2016-04-22 2025-04-11 即効性の植物由来医薬化合物及び栄養補給剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019506612A Active JP6983868B2 (ja) 2016-04-22 2017-04-21 即効性の植物由来医薬化合物及び栄養補給剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023081364A Active JP7671079B2 (ja) 2016-04-22 2023-05-17 即効性の植物由来医薬化合物及び栄養補給剤
JP2025065534A Pending JP2025108565A (ja) 2016-04-22 2025-04-11 即効性の植物由来医薬化合物及び栄養補給剤

Country Status (13)

Country Link
US (5) US10588974B2 (https=)
EP (2) EP3928776B1 (https=)
JP (4) JP6983868B2 (https=)
KR (1) KR102393596B1 (https=)
CN (1) CN109069475B (https=)
AU (3) AU2017252575B2 (https=)
BR (1) BR112018071518A2 (https=)
CA (1) CA3021660A1 (https=)
CL (1) CL2018002997A1 (https=)
CO (1) CO2018011299A2 (https=)
IL (2) IL262505B (https=)
MX (2) MX382853B (https=)
WO (1) WO2017185038A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12137716B2 (en) 2015-04-16 2024-11-12 Michael Hudnall Methods of liver disease treatment
EP3928776B1 (en) 2016-04-22 2025-11-12 Spoke Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) * 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
KR20190103302A (ko) * 2017-01-03 2019-09-04 리셉터 홀딩스, 인크. 의약 화합물 및 영양 보충제
EA201992247A1 (ru) * 2017-03-23 2020-03-24 Ресептор Холдингз, Инк. Быстрая и контролируемая доставка композиций с восстановленным эффектом антуража
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
US20190321330A1 (en) * 2018-04-18 2019-10-24 Canopy Growth Corporation Cannabis placebo compositions, delivery vehicles and a method for colour matching/neutralization of cannabis products
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
AU2019385420A1 (en) * 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
US20200215024A1 (en) * 2019-01-08 2020-07-09 Replennabis LLC Cannabinoid formulations for treating alcohol hangover
WO2020163866A1 (en) * 2019-02-08 2020-08-13 Schedule 1 Therapeutics, Inc. Compositions comprising cannabinoids and methods of use thereof
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders
JP2022539400A (ja) * 2019-07-04 2022-09-08 キャノピー グロウス コーポレイション カンナビノイド誘導体
EP3997098A4 (en) 2019-07-12 2023-10-11 Canopy Growth Corporation CANNABINOIDS DERIVATIVES
EP3946262B1 (en) 2019-08-30 2024-07-31 Evie Sa Loaded granules, their process of production and their uses
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
CN112661663B (zh) * 2020-05-29 2021-09-17 杭州先为达生物科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸钾晶体多晶型物及其制备方法和用途
ES3030918T3 (en) 2020-05-29 2025-07-02 Sciwind Biosciences Co Ltd N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US20230047027A1 (en) * 2021-07-13 2023-02-16 Demetrix, Inc. Compositions and methods using cannabinoid compounds for regulating gastric acid secretion to treat gastroesophageal reflux disease and related conditions
WO2023091173A1 (en) * 2021-11-16 2023-05-25 Michael Hudnall Methods of liver disease treatment
CN114539091B (zh) * 2022-03-11 2024-11-05 佛山奕安赛医药科技有限公司 异棕榈酰氨基酸类化合物及其制备方法和应用
CN116474049A (zh) * 2023-03-17 2023-07-25 深圳福图仁泰生物科技有限公司 一种兼具抗抑郁和促睡眠功效的植物天然水溶性复合物及其制备方法和应用
WO2025054536A1 (en) * 2023-09-07 2025-03-13 The Regents Of The University Of California Cannabinoid delivery

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2385365A (en) 1943-02-17 1945-09-25 Wisconsin Alumni Res Found Salicylic acid compounds for safer therapeutic use
US3939259A (en) 1974-05-24 1976-02-17 Anthony Pescetti Coating composition and therapeutic preparation incorporating same
DE2537232B2 (de) 1974-08-22 1976-07-01 Spritz- und formmasse
US4374082A (en) 1981-08-18 1983-02-15 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form
EP0273209B1 (en) 1986-12-30 1992-01-15 American Cyanamid Company Composition of matter containing polycarbophil
US4758597A (en) 1987-05-15 1988-07-19 University Patents, Inc. Carenadiol and derivatives
US4902513A (en) 1987-07-31 1990-02-20 Jean Carvais Oral sustained release medicament
US5965162A (en) 1993-09-10 1999-10-12 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
EP1049474A4 (en) 1998-11-24 2004-12-29 Univ Connecticut CANNABIMIMETIC LIPID AMIDES FOR USE AS MEDICINES
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US6495177B1 (en) 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
CN100391438C (zh) 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
EP1231273A1 (en) 2001-02-12 2002-08-14 Plant Research International B.V. Terpene synthase/cyclase and olefin synthase and uses thereof
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB2377633A (en) 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
IL158322A0 (en) 2001-04-18 2004-05-12 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
IL143318A0 (en) 2001-05-23 2002-04-21 Herbal Synthesis Corp Herbal compositions for the treatment of mucosal lesions
AU2002352974A1 (en) * 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
JP2006509038A (ja) 2002-12-04 2006-03-16 ファーモス コーポレイション 医薬組成物用の高エナンチオマー純度を有するデキサナビノール
EP1572164A2 (en) 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AU2004296877A1 (en) 2003-12-09 2005-06-23 Incyte Corporation Dosing methods for ss-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
CA2551946A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
IL162636A0 (en) 2004-06-20 2005-11-20 Yissum Res Dev Co Resorcinol derivatives and their use for lowering blood pressure
CN101076324A (zh) 2004-10-22 2007-11-21 法玛氏公司 口服有效的大麻素类似物
TW200843761A (en) 2004-10-28 2008-11-16 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
GB0507167D0 (en) 2005-04-08 2005-05-18 Glaxosmithkline Consumer Healt Composition
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
JP5430929B2 (ja) 2005-06-17 2014-03-05 フイルメニツヒ ソシエテ アノニム 新規セスキテルペン合成酵素ならびにその使用方法
WO2008134071A1 (en) 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
PT1903866E (pt) 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
AR059035A1 (es) 2006-01-16 2008-03-12 Syngenta Participations Ag Insecticidas derivados de antranilamida
US20070254911A1 (en) 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
KR101575679B1 (ko) 2006-08-30 2015-12-08 자고텍 아게 코어 및 하나 이상의 배리어 층을 포함하는 방출 제어형 경구 투여 제제
GB0624340D0 (en) 2006-12-06 2007-01-17 Nature Therapeutics Ltd Antimicrobial composition
WO2008118414A1 (en) 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
NZ585080A (en) 2007-11-02 2012-05-25 Emisphere Tech Inc Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency
US20090155392A1 (en) 2007-12-17 2009-06-18 Bret David Nelson Methods and Systems for Sublingual Guarana Administration
WO2009100245A1 (en) 2008-02-05 2009-08-13 Emisphere Technologies Inc. Low dose hmg-coa reductase inhibitor with reduced side effects
US20110137040A1 (en) 2008-08-01 2011-06-09 Lange Josephus H M Synthesis of 3,4-diaryl-4,5-dihydro-(h)-pyrazole-1-carboxamidine derivatives
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
CN101439074B (zh) 2008-12-11 2012-06-06 深圳海王药业有限公司 苍术总萜醇提取物及其制备方法和用途
MX2011011514A (es) 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
WO2011087755A2 (en) * 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
NZ609356A (en) 2010-11-25 2014-10-31 Aop Orphan Pharmaceuticals Ag Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin
WO2013032934A1 (en) 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
ES2806034T3 (es) 2011-09-29 2021-02-16 Thc Pharm Gmbh The Health Concept Acidos carboxílicos de cannabinoide, sales de ácidos carboxílicos de cannabinoide, su preparación y aplicaciones
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
MX2014010926A (es) 2012-03-13 2015-04-10 Piramal Entpr Ltd Composicion herbaria para el tratamiento de transtornos metabolicos.
AU2013257322A1 (en) 2012-05-03 2014-11-20 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising delta9-tetrahydrocannabinol and a method for preparing such an isolate
ES2554130T3 (es) 2012-05-23 2015-12-16 Tergum S.L. Extracto de terpenos para el tratamiento de la caída del cabello
CN104884065B (zh) 2012-09-21 2019-01-01 强烈治疗剂公司 治疗癌症的方法
US20150273069A1 (en) 2012-10-17 2015-10-01 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US10639439B2 (en) 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
WO2014134281A1 (en) 2013-02-28 2014-09-04 Full Spectrum Laboratories Limited Biosynthesis of cannabinoids
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
CN105142618A (zh) 2013-03-15 2015-12-09 韩国联合制药株式会社 提供药理及临床效应的莫沙必利每日单次施用缓释制剂
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US9326967B2 (en) 2013-08-22 2016-05-03 Stephen C. Perry Vaporizable cannabinoid compositions
US9532593B2 (en) * 2013-12-26 2017-01-03 John Turner Herbal smoking blend
WO2015118549A1 (en) 2014-02-10 2015-08-13 F&C Licorice Ltd. Encapsulated biologically active agents
CA2845443A1 (en) 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
WO2016022936A1 (en) * 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
BR112017018316A2 (pt) 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
WO2016205923A1 (en) 2015-06-25 2016-12-29 Compressed Perforated Puck Technologies Inc. Ingestible plant source pill and method
EP3928776B1 (en) * 2016-04-22 2025-11-12 Spoke Sciences, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
KR20190103302A (ko) 2017-01-03 2019-09-04 리셉터 홀딩스, 인크. 의약 화합물 및 영양 보충제
US10772837B2 (en) 2017-03-16 2020-09-15 CannTab Therapeutics, Ltd Modified release multi-layer tablet cannabinoid formulations
EA201992247A1 (ru) 2017-03-23 2020-03-24 Ресептор Холдингз, Инк. Быстрая и контролируемая доставка композиций с восстановленным эффектом антуража
CA3078549A1 (en) 2017-10-05 2019-04-11 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations
MX2020003330A (es) 2017-10-05 2020-07-28 Receptor Holdings Inc Composiciones de hierbas con mejor biodisponibilidad.

Similar Documents

Publication Publication Date Title
JP2022031762A5 (https=)
JP2023071697A5 (https=)
JP2020500876A5 (https=)
JP2019515031A5 (https=)
JP2020503357A5 (https=)
AU2016329526B2 (en) Vacuum distillation for enriching cannabidiol
Ribeiro et al. Modulation of human neutrophils' oxidative burst by flavonoids
Khan et al. Biscoumarin: new class of urease inhibitors; economical synthesis and activity
JP2019530751A5 (https=)
CA3057129C (en) Compositions and methods for managing or improving bone disorders, cartilage disorders, or both
IL275704B2 (en) Oral pharmaceutical formulation comprising cannabinoids and poloxamer
RU2020125295A (ru) Состав с модифицированным высвобождением, содержащий каннабиноид
BR0316595A (pt) Composto, método para a preparação de compostos, composição farmacêutica e usos do composto
IL177219A0 (en) Medicinal acidic cannabinoids
BR0208103A (pt) Composição para a prevenção de osteoporose compreendendo uma combinação de isoflavonas e ácidos graxos poliinsaturados
PE20200383A1 (es) Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados
CN101811968B (zh) 多官能团化苯甲酰甲酸羟基酮酯类化合物及含有该类化合物的光引发剂
FI3920890T3 (fi) Oraalinen kannabinoiditabletti
Kuwabara et al. Analysis of supercooling activity of tannin-related polyphenols
Reggio et al. Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach
GB2597170A (en) Diluents for compositions of cannabinoids and uses thereof
DE602004020463D1 (de) Isoflavonderivative von tectoridin, deren herstellung und antivirale medikamente, die diese als wirksame bestandteile enthalten
US20210085640A1 (en) Acylated catechin polyphenols and methods of their use for the treatment of cancer
BR0308779A (pt) Composição farmacêutica, e, método de preparação da mesma
Muhaisen Chemical constituents from the bark of Lannea acida Rich (Anacardiaceae)